Suppr超能文献

[评估心力衰竭中血管扩张剂的方法]

[Methods for evaluating vasodilator agents in cardiac failure].

作者信息

Dahan M

机构信息

Service de cardiologie, hôpital Bichat, Paris.

出版信息

Arch Mal Coeur Vaiss. 1990 Mar;83 Spec No 2:63-7.

PMID:2111689
Abstract

Invasive cardiac catheterisation remains the reference technique for the evaluation of the effects of vasodilator drugs in cardiac failure. The arterial, venous or mixed site of action can be determined. Venous vasodilators induce a fall in left ventricular end diastolic volume (EVD), left ventricular end diastolic pressure (EDP), and stroke volume (SV). Arterial vasodilators decrease left ventricular end systolic pressure (ESP), end systolic volume (ESV) and increase the stroke volume. Mixed vasodilators associate the effects of both, leading to a fall in left ventricular filling pressures and an increase in SV. It is not always easy to determine the exact site of action of a given vasodilator drug. Arterial vasodilatation can only be confirmed when peripheral arterial resistances and systemic blood pressure decrease simultaneously. Venous vasodilatation can only be formally confirmed by using other techniques such as pethysmography. Hemodynamic investigations have other fundamental objectives in the evaluation of the effects of a vasodilator, especially the demonstration of possible associated positive inotropic effects. This would be relatively easy in the case of a venous vasodilator which induces an increase in SV but more difficult in the assessment of an arterial vasodilator. Studying the distribution of regional blood flow after the administration of a vasodilator is another important objective of cardiac catheterisation. Although coronary flow can be studied properly, the hemodynamics of other regions can only be assessed approximatively. The phenomenon of tolerance at an early or late stage of vasodilator therapy can also be demonstrated by hemodynamic monitoring.

摘要

有创心脏导管检查仍是评估血管扩张药物对心力衰竭疗效的参考技术。可以确定其动脉、静脉或混合作用部位。静脉血管扩张剂可使左心室舒张末期容积(EVD)、左心室舒张末期压力(EDP)和每搏量(SV)下降。动脉血管扩张剂可降低左心室收缩末期压力(ESP)、收缩末期容积(ESV)并增加每搏量。混合血管扩张剂兼具两者的作用,导致左心室充盈压下降和每搏量增加。确定某一特定血管扩张药物的确切作用部位并非总是易事。只有当外周动脉阻力和全身血压同时下降时,才能证实存在动脉血管扩张。静脉血管扩张只能通过使用其他技术(如体积描记法)来正式确认。血流动力学研究在评估血管扩张剂的作用方面还有其他基本目标,尤其是证明可能存在的相关正性肌力作用。对于能使每搏量增加的静脉血管扩张剂来说,这相对容易,但在评估动脉血管扩张剂时则更困难。研究血管扩张剂给药后局部血流的分布是心脏导管检查的另一个重要目标。虽然冠状动脉血流可以得到恰当研究,但其他区域的血流动力学只能进行大致评估。血管扩张剂治疗早期或晚期的耐受性现象也可通过血流动力学监测来证实。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验